News

For some leukemia patients, the only potential chemotherapy option is a drug that also carries a high risk of heart failure. This means that some patients who recover from their cancer will end up dying of heart disease brought on by the cure.

Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment.

Current immunotherapies work only against cancers of the blood and bone marrow. T cells engineered by Northwestern and UCSF were able to kill tumors derived from skin, lung and stomach in mice.

Researchers have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can restore the effectiveness of the breast cancer drug T-DM1 if the cancer cells have developed resistance.

A joint research team has used stem cells to generate human immune cells for application in cancer immunotherapy. This breakthrough platform is expected to significantly enhance cancer-targeting efficacy.

A multinational team of researchers led by Columbia University has discovered that tumors can repurpose a single cellular protein to hide themselves from the immune system in two distinct ways.

Monash University-led research is using maths to predict how new combination therapies can help patients with breast cancer who no longer respond to conventional therapies.

Blood tests could predict outcomes of CAR T-cell therapy, helping to optimize cancer treatments and improve their safety and efficacy.

Researchers described the effects of chemotherapy at the single cell resolution in the bone marrow of Myelodysplastic Syndrome patients. The results help better understand which cellular populations are more sensitive to an epigenetic drug.

A promising drug could lead to a new treatment for the most aggressive form of breast cancer, which affects thousands of women each year. A pre-clinical study found the new drug successfully inhibits the growth of triple negative breast cancer.